Analysis of pravastatin to prevent recurrence of atrial fibrillation after electrical cardioversion

Arnljot Tveit; Morten Grundtvig; Torstein Gundersen; Paul Vanberg; Anne Grete Semb; Even Holt; Lars Gullestad

doi:10.1016/j.amjcard.2003.12.009

Analysis of pravastatin to prevent recurrence of atrial fibrillation after electrical cardioversion

Am J Cardiol. 2004 Mar 15;93(6):780-2. doi: 10.1016/j.amjcard.2003.12.009.

Authors

Arnljot Tveit¹, Morten Grundtvig, Torstein Gundersen, Paul Vanberg, Anne Grete Semb, Even Holt, Lars Gullestad

Affiliation

¹ Department of Internal Medicine, Asker & Baerum Hospital, Rud, Norway. arnljot.tveit@broadpark.no

PMID: 15019894
DOI: 10.1016/j.amjcard.2003.12.009

Abstract

To test the hypothesis that a statin could reduce the recurrence rate of atrial fibrillation after electrical cardioversion (EC), we performed an open, controlled multicenter study. Patients (n = 114) who had atrial fibrillation >48 hours and who were scheduled for EC were randomized to receive 40 mg of pravastatin once daily for 3 weeks before and 6 weeks after EC or no drug in addition to standard therapy. Pravastatin did not reduce the recurrence rate of atrial fibrillation after EC.

Publication types

Clinical Trial
Multicenter Study
Randomized Controlled Trial

MeSH terms

Adult
Aged
Aged, 80 and over
Atrial Fibrillation / prevention & control*
Atrial Fibrillation / therapy
Drug Administration Schedule
Electric Countershock
Female
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Male
Middle Aged
Norway
Pravastatin / administration & dosage
Pravastatin / therapeutic use*
Secondary Prevention
Treatment Outcome

Substances

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Pravastatin